Zach Rozenbaum
Interventional Cardiology · New Orleans, LANPI 1952929077
Payments from drug & device makers
Across 130 payments — averaging $138.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$10K
- Edwards Lifesciences$3K
- Abbott$2K
- Abiomed$1K
- Medtronic$641
- Inari Medical, Inc.$364
- plus $1K from 11 others
What the payments were for
- Consulting fees$7,60042%
- Travel & lodging$2,46114%
- Food & beverage$7,94744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 24 | $9,991 |
| Edwards Lifesciences | 28 | $2,615 |
| Abbott | 22 | $1,683 |
| Abiomed | 13 | $1,238 |
| Medtronic | 11 | $641 |
| Inari Medical, Inc. | 6 | $364 |
| Philips North America LLC | 5 | $311 |
| W. L. Gore & Associates, Inc. | 2 | $211 |
| Shockwave Medical, Inc | 2 | $207 |
| Livanova USA, Inc. | 4 | $169 |
| Boston Scientific | 2 | $148 |
| Alnylam Pharmaceuticals Inc. | 5 | $131 |
| Amgen | 1 | $102 |
| Siemens Medical Solutions USA, Inc. | 1 | $96 |
| Baxter Healthcare | 1 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AlphaVac$9,228
- EVOQUE$1,228
- Impella$821
- TRICLIP$566
- MitraClip$428
- COREVALVE EVOLUT R$413
- SAPIEN 3 Ultra RESILIA$348
- FLOWTRIEVER CATHETER, S$275
- CT THROMBECTOMY SYSTEM KIT$275
- GORE CARDIOFORM Septal Occluder$172
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$156
- AVVIGO Guidance System$134
- OPTIS$125
- (4067) Tack Endovascular Systems BTK$123
- Repatha$102
How this compares
$18,009 in reported general payments places this provider in the 60th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $19,766 |
| EntrestoSacubitril/Valsartan | 11 | $6,854 |
| Atorvastatin Calcium | 26 | $293 |
| ClopidogrelClopidogrel Bisulfate | 38 | $256 |
| Ezetimibe | 22 | $214 |
| Furosemide | 29 | $190 |
| Losartan Potassium | 18 | $136 |
| Metoprolol Succinate | 16 | $132 |
| Spironolactone | 16 | $74 |
| Amlodipine Besylate | 17 | $52 |
| Carvedilol | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in New Orleans
- Stephen RameeNew Orleans$1.5M
- James JenkinsNew Orleans$1.2M
- Rajan PatelNew Orleans$633K
- Jose Tafur SotoNew Orleans$419K
- Anand IrimpenNew Orleans$100K
- George YousefNew Orleans$99K
- Jose WileyNew Orleans$77K
- Murtuza AliNew Orleans$65K
- Madhur RobertsNew Orleans$28K
- Craig WalkerHouma$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.